Do analysts prefer TRAW or INCR?

Traws Pharma currently has a consensus price target of $8.00, suggesting a potential upside of 469.40%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TRAW or INCR more profitable?

InterCure's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% InterCure N/A N/A N/A

Is TRAW or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Dogwood Therapeutics N/A -108.57% -30.28%

Is HYPD or TRAW more profitable?

Hyperion DeFi's return on equity of -91.59% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Traws Pharma N/A -913.18% -133.88%

Is TRAW or TIL more profitable?

Instil Bio's return on equity of -39.76% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Instil Bio N/A -39.76% -22.38%

Is TRAW or CING more profitable?

Cingulate's return on equity of -365.15% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Cingulate N/A -365.15% -158.55%

Traws Pharma (TRAW) Competitors

$1.40 +0.04 (+2.55%)

As of 03:09 PM Eastern

Compare

TRAW vs. INCR, DWTX, HYPD, TIL, and CING

Should you buy Traws Pharma stock or one of its competitors? MarketBeat compares Traws Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Traws Pharma include InterCure (INCR), Dogwood Therapeutics (DWTX), Hyperion DeFi (HYPD), Instil Bio (TIL), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry.

How does Traws Pharma compare to InterCure?

Traws Pharma (NASDAQ:TRAW) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Traws Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, InterCure has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Traws Pharma has higher earnings, but lower revenue than InterCure. Traws Pharma is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.73M	5.22	$9.17M	-$1.69	N/A
InterCure	$78.47M	0.70	-$10.37M	$0.03	33.70

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
InterCure	Neutral

InterCure's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
InterCure	N/A	N/A	N/A

Traws Pharma currently has a consensus price target of $8.00, suggesting a potential upside of 469.40%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Traws Pharma beats InterCure on 8 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to Dogwood Therapeutics?

Traws Pharma (NASDAQ:TRAW) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled Dogwood Therapeutics'average media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
Dogwood Therapeutics	Neutral

Dogwood Therapeutics' return on equity of -108.57% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Traws Pharma has higher revenue and earnings than Dogwood Therapeutics. Traws Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.73M	5.22	$9.17M	-$1.69	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Traws Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Traws Pharma presently has a consensus price target of $8.00, indicating a potential upside of 469.40%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 707.54%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 14.0% of Traws Pharma shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Traws Pharma and Dogwood Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Traws Pharma compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Hyperion DeFi had 7 more articles in the media than Traws Pharma. MarketBeat recorded 7 mentions for Hyperion DeFi and 0 mentions for Traws Pharma. Hyperion DeFi's average media sentiment score of 0.98 beat Traws Pharma's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Traws Pharma	Neutral

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 7.9% of Traws Pharma shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 14.0% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hyperion DeFi has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Hyperion DeFi's return on equity of -91.59% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Traws Pharma	N/A	-913.18%	-133.88%

Traws Pharma has higher revenue and earnings than Hyperion DeFi. Traws Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	41.07	-$45.31M	-$9.95	N/A
Traws Pharma	$2.73M	5.22	$9.17M	-$1.69	N/A

Hyperion DeFi currently has a consensus price target of $5.65, indicating a potential upside of 99.93%. Traws Pharma has a consensus price target of $8.00, indicating a potential upside of 469.40%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Traws Pharma is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Hyperion DeFi beats Traws Pharma on 8 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to Instil Bio?

Traws Pharma (NASDAQ:TRAW) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
Instil Bio	Neutral

Instil Bio's return on equity of -39.76% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Instil Bio	N/A	-39.76%	-22.38%

Traws Pharma has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.73M	5.22	$9.17M	-$1.69	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Traws Pharma currently has a consensus target price of $8.00, suggesting a potential upside of 469.40%. Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 720.18%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 14.0% of Traws Pharma shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Traws Pharma has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Summary

Traws Pharma beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Traws Pharma compare to Cingulate?

Traws Pharma (NASDAQ:TRAW) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Traws Pharma has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.73M	5.22	$9.17M	-$1.69	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 14.0% of Traws Pharma shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cingulate had 10 more articles in the media than Traws Pharma. MarketBeat recorded 10 mentions for Cingulate and 0 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.00 beat Cingulate's score of -0.10 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Neutral
Cingulate	Neutral

Traws Pharma presently has a consensus price target of $8.00, suggesting a potential upside of 469.40%. Cingulate has a consensus price target of $27.33, suggesting a potential upside of 510.12%. Given Cingulate's higher possible upside, analysts plainly believe Cingulate is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Traws Pharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market.

Cingulate's return on equity of -365.15% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Cingulate	N/A	-365.15%	-158.55%

Summary

Traws Pharma beats Cingulate on 9 of the 14 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAW vs. The Competition

Export

Metric	Traws Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.27M	$2.95B	$6.44B	$12.09B
Dividend Yield	N/A	1.69%	2.67%	5.56%
P/E Ratio	-0.83	17.75	23.80	23.78
Price / Sales	5.22	295.78	479.35	86.31
Price / Cash	1.79	56.17	26.99	37.25
Price / Book	-20.07	3.83	10.36	6.80
Net Income	$9.17M	$75.85M	$3.57B	$337.51M
7 Day Performance	-4.42%	-4.72%	-1.27%	-2.64%
1 Month Performance	-35.55%	-6.05%	3.17%	1.90%
1 Year Performance	-14.85%	15.18%	23.59%	26.94%

Traws Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAW Traws Pharma	2.5682 of 5 stars	$1.41 +2.6%	$8.00 +469.4%	-17.0%	$14.27M	$2.73M	N/A	17	Gap Up
INCR InterCure	0.8056 of 5 stars	$1.04 +1.0%	N/A	-32.0%	$56.32M	$78.47M	34.67	350
DWTX Dogwood Therapeutics	3.2197 of 5 stars	$1.61 -3.6%	$12.00 +645.3%	-69.3%	$56.16M	N/A	N/A	5	Gap Up
HYPD Hyperion DeFi	4.2815 of 5 stars	$3.61 -2.4%	$5.88 +62.7%	-38.7%	$56.08M	$810K	N/A	40	News Coverage Analyst Forecast Gap Up
TIL Instil Bio	2.1984 of 5 stars	$8.23 +1.5%	$66.00 +701.9%	-75.5%	$55M	N/A	N/A	410	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAW) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Traws Pharma (TRAW) Competitors

TRAW vs. INCR, DWTX, HYPD, TIL, and CING

How does Traws Pharma compare to InterCure?

Summary

How does Traws Pharma compare to Dogwood Therapeutics?

Summary

How does Traws Pharma compare to Hyperion DeFi?

Summary

How does Traws Pharma compare to Instil Bio?

Summary

How does Traws Pharma compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Traws Pharma (TRAW) Competitors

TRAW vs. INCR, DWTX, HYPD, TIL, and CING

How does Traws Pharma compare to InterCure?

Which has more risk and volatility, TRAW or INCR?

Which has preferable earnings and valuation, TRAW or INCR?

Does the media refer more to TRAW or INCR?

Is TRAW or INCR more profitable?

Do analysts prefer TRAW or INCR?

Do insiders & institutionals hold more shares of TRAW or INCR?

Summary

How does Traws Pharma compare to Dogwood Therapeutics?

Does the media refer more to TRAW or DWTX?

Is TRAW or DWTX more profitable?

Which has preferable earnings & valuation, TRAW or DWTX?

Which has more volatility and risk, TRAW or DWTX?

Do analysts prefer TRAW or DWTX?

Do institutionals and insiders believe in TRAW or DWTX?

Summary

How does Traws Pharma compare to Hyperion DeFi?

Does the media favor HYPD or TRAW?

Do insiders & institutionals believe in HYPD or TRAW?

Which has more risk & volatility, HYPD or TRAW?

Is HYPD or TRAW more profitable?

Which has higher valuation & earnings, HYPD or TRAW?

Do analysts recommend HYPD or TRAW?

Summary

How does Traws Pharma compare to Instil Bio?

Does the media refer more to TRAW or TIL?

Is TRAW or TIL more profitable?

Which has better valuation and earnings, TRAW or TIL?

Do analysts recommend TRAW or TIL?

Do institutionals and insiders have more ownership in TRAW or TIL?

Which has more volatility & risk, TRAW or TIL?

Summary

How does Traws Pharma compare to Cingulate?

Which has better earnings and valuation, TRAW or CING?

Do institutionals & insiders have more ownership in TRAW or CING?

Does the media refer more to TRAW or CING?

Do analysts rate TRAW or CING?

Which has more risk & volatility, TRAW or CING?

Is TRAW or CING more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools